# Digital Data Flow (DDF) Project Public Review

Dave Evans, CDISC President & CEO Dave Iberson-Hurst, CDISC DDF Technical Product Owner Alison Luckman, TransCelerate co-Product Owner/Lead for the DDF Delivery/Build Team John Owen, CDISC Head PMO

cdisc

TUE 22 MAR 2022 11:00AM-12:30PM ET

# Today's Agenda


1. Housekeeping

2

- 2. Speaker Introductions
- 3. Feature Presentation
- 4. Upcoming Learning Opportunities & Events

# Housekeeping


3






# You will remain on mute








# Submit questions at any time via the Questions tool on your GTW app




### Housekeeping



### Audio issues?

Shut down & restart GoToWebinar app






### Housekeeping



A recording of this webinar and the slides will be available in the **Members Only** section of CDISC website





### **Today's Presenters**

**Dave Evans** 

President & CEO CDISC

# Alison Luckman

co-Product Owner/Lead for the DDF Delivery/Build Team TransCelerate

# **Dave Iberson-Hurst**

DDF Technical Product Owner CDISC

# John Owen

Head PMO CDISC



# Digital Data Flow (DDF) Project Public Review

Dave Evans, CDISC President & CEO Dave Iberson-Hurst, CDISC DDF Technical Product Owner Alison Luckman, TransCelerate co-Product Owner/Lead for the DDF Delivery/Build Team John Owen, CDISC Head PMO

cdisc

TUE 22 MAR 2022 11:00AM-12:30PM ET

### Digital Data Flow (DDF) Project Public Review Webinar

Presenters:

Dave Evans, CDISC President & CEO

Dave Iberson-Hurst, CDISC DDF Technical Product Owner

Alison Luckman, TransCelerate co-Product Owner/Lead for the DDF Delivery/Build Team

John Owen, CDISC Head PMO

# cdisc

### 1. Webinar Introduction

- 2. TransCelerate and DDF
- 3. CDISC DDF standards for public review
- 4. Public Review Process
- 5. Q&A

# Why is CDISC partnering with TransCelerate on DDF?

CDISC has always been an evolving transformational standards organization for information used in clinical research and regulatory submission.

### **CDISC Data Standards Lifecycle**





# Why is CDISC partnering with TransCelerate on DDF?


CDISC has always been an evolving transformational standards organization for information used in clinical research and regulatory submission.

### **CDISC Data Standards Lifecycle**

### Automation requires:

- Standard Machine-executable content for Useability
- Standard Technology Interfaces for Integration for Accessibility
- Standard Verification and Conformance Rules for Integrity
- Standard Trial Design Specifications for Total Automation of the Digital Data Flow






cdisc

**CDISC Standards** 


Informative Content

# **The Clinical Trial Information Flow**



cdisc

# **The Clinical Trial Information Flow**



cdisc

### 1. Webinar Introduction


### 2. TransCelerate and DDF

- 3. CDISC DDF standards for public review
- 4. Public Review Process
- 5. Q&A

### The Digital Data Flow Initiative (DDF) aims to catalyze digital transformation; breaking the document paradigm to enable seamless flow of the data within:

#### **Digitized Protocols**

Enabling the use of technologies that identify and assemble study elements allows industry to move to digital protocols



#### **Connectivity of Data and Processes**

Enabling traceability, automated flow of content to key clinical documents, and automation to clinical & operational systems (e.g., EDC, CTMS)

#### **Open and Flexible Solution**

Developing a dynamic, fully automated solution that is vendor agnostic, open and flexible

#### Development principles to enable broad collaboration, stakeholder input, and sustainability





**Vendor Agnostic** 



**Agile Development** 




**Dynamic Alignment** to Standards





cdisc

## Minimum Viable Product (MVP) development underway



\* Solution Providers above have volunteered to participate in MVP development in anticipation of making use of DDF solutions in the future. Additional Solution Providers may volunteer in coming weeks/months. TransCelerate does not endorse nor recommend specific vendors or commercial products.

# **Enabling DDF – Where are we on the DDF journey?**



Initial discussions and alignment between technical solution teams (RA/RI for USDM, SDR) and Study Builders, EDC vendors to collaborate on SDR design compatibility to receive and send data Digitizing a portion of the study data elements included in the Common Protocol Template significantly facilitates for automated Protocol Document enablement Digitizing a portion of the study data elements enables partial automated EDC build



### **Engaging with DDF**

•What's Coming?

# DDF GitHub Launch for Open-source (OS) Collaboration

Launch of DDF GitHub site to foster, develop, and maintain an opensource community of active DDF project contributors. GitHub repository will be the central destination for OS material & future collaboration.

### DDF Connectathon

Planned Connectathon event in 2022 will encourage demonstrations of use/connectivity to the Study Definitions Repository & CDISC standards by anyone in the vendor community.

#### Resources to Learn More (Click on any of icons/links below.)







- 2. TransCelerate and DDF
- 3. CDISC DDF standards for public review
- 4. Public Review Process
- 5. Q&A

# **CDISC Study Definition Repository RA Deliverables**



#### Unified Study Definitions Model (USDM) Class Diagram

The UML class diagram (normative) as well as SQL Data Dictionary, Entity Relationship Diagram and example JSON output (informative)



#### Application Programming Interface (API) Specification The API definition (normative) in JSON and HTML forms



#### **CDISC Controlled Terminology**

The controlled terminology (normative) developed for the project. Provided in an Excel format so as to be easily searched and filtered.



#### **Reference Architecture Conformance Tests**

Provided by the functionality provided by tools such as SwaggerHub and Postman



#### **Essential Users Stories** The User Stories. PDF document

\$ \$ \$

#### Architecture Principles

The architectural principles developed by the project. PDF Document

#### **Supporting Materials**


A set of informational materials in PDF format to help understand the deliverables being reviewed. PDF documents or references.





#### Unified Study Definitions Model (USDM) Class Diagram

The UML class diagram (normative) as well as SQL Data Dictionary, Entity Relationship Diagram and example JSON output (informative)






........

.....

#### Unified Study Definitions Model (USDM) Class Diagram

The UML class diagram (normative) as well as SQL Data Dictionary, Entity Relationship Diagram and example JSON output (informative)





· ...

........

171 H

.....

.......

.....

....

......

.....

........

. . . . . . . . .

#### Unified Study Definitions Model (USDM) Class Diagram

The UML class diagram (normative) as well as SQL Data Dictionary. Entity Relationship Diagram and example JSON output (informative)





### Application Programming Interface (API) Specification The API definition (normative) in JSON and HTML forms

et history of all studies (get.studydesignrepository.history)	"openapi": "3.0.0",	JSOI
et history of all studies	"info": {	
eturn type <u>line response 200 1</u> xample data	"title": "Simple API for DDF", "description": "This is a sample API for the DDF project - including se "license": { "name": "MIT", "url": "https://opensource.org/licenses/MIT"	ctioning (Acc
<pre>ontent-Type: application/json {     "study": [ {         "studyVersion": [ 1, 1 ],         "studyVersion": "e3e84e94-927e-42da-9625-e4f18bc4b7a4",         "studyTitle": "Example study title" }, { </pre>	<pre>}, "version": "1.2.6" }, "servers": [ {     "url": "https://virtserver.swaggerhub.com/CDISC1/DDF/1.2.6",</pre>	
"studyVersion" : [ 1, 1 ], "studyId" : "e3e84e94-927e-42da-9625-e4f18bc4b7a4", "studyTitle" : "Example study title" } ] }	<pre>"description": "SwaggerHub API Auto Mocking" } ], "paths": {     "/studydefinitionrepository/v1/{study}": {         "get": {         "get": {</pre>	
<pre>roduces his API call produces the following media types according to the Accept request header; the media type will be conve • application/json</pre>		
K Inline_response_200_1	<pre>"description": "Get Study Build Sections", "operationId": "get.studydesignrepository.sections", "parameters": [</pre>	
his Set	"name": "study", "in": "path", "description": "Study Builder Study", "required": true,	
<ul> <li><u>GET /studydefinitionrepository/vl/studyhistory</u></li> <li><u>GET /studydefinitionrepository/vl/(study)/sectionhistory</u></li> <li><u>GET /studydefinitionrepository/vl/(study)/studydesign/(s</u></li> <li><u>GET /studydefinitionrepository/vl/(study)/studydesign/(s</u></li> <li><u>GET /studydefinitionrepository/vl/(study)/studyprotocols</u></li> <li><u>POST /studydefinitionrepository/vl/(study)/studyprotocols</u></li> <li><u>POST /studydefinitionrepository/vl/(study)/studyprotocols</u></li> </ul>	<pre>/ "style": "simple", "explode": false, "schema": { "type": "string", "example": "ACME001"</pre>	
gnore!		
POST /studydefinitionrepository/vl/components     DELETE /studydefinitionrepository/vl/{study}/studyassess		



**CDISC Controlled Terminology** The controlled terminology (normative) developed for the project. Provided in an Excel format so as to be easily searched and filtered.

5         C         C         Response           5         STUDY         study_protocol_version         Attribute         C93490         Study Protocol Version         A plan at a particular point in time for a formal investigation to assess the utility, impact of the investigation for which study information is being collected. (After clinical triatesment, procedure, drug, device, logic, tood product, cosmetic, care plan, or stubject characteristic. (BRIDG)         N           6         STUDY_TYPE         STUDY_TYPE         Entity         C142175         Study Type: Study Type: Classification         The nature of the investigation for which study information is being collected. (After clinical triats gov)         N           7         STUDY_TYPE         study_type_desc         Attribute         C142175         Study Type: Classification         Collected. (After clinical triats gov)         Y (C98)           8         STUDY_PHASE         STUDY_PHASE         Entity         C48281         Trial Phase         Trial Phase         A step in the clinical research and development of a therapy from initial N clinical triats to post-approval studies. NOTE: Clinical triats to asses simultaneously in different triats, and some triats may overiap two different phases. [21 CFR section 312.21; Atter CH Topic E NOTE FOR GUIDAKCE ON GENERAL CONSIDERATION SPOR CLINICAL TRIALS, CPMPICH/219168 March 1998]           9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase: Classification         A step in the	1	Row #	UML Class Name	UML Item Name	Role	NCIC-	CT Item Preferred Name	Synonym(s)	Definition	Has Value List
2         3         5         STUDY         stady_title         Attribute         Clinical Studies         Clinical Traits (also called interventional studies) and observational studies. Interventional studies)         N           3         STUDY         stady_title         Attribute         Clinical Trait Tritle; Official Study Tritle; Study Tritle         Triat Tritle; Official Study Tritle; Study Tritle         A plan at a particular point in time for a formal investigation to assess the utility, inpact, pharmacological, physiological, and/or product, commerc, care plan, or subject characteristic. (BRIDO)         N           4         STUDY         study_status         Abribute         CNEW         Protocol Version         A plan at a particular point in time for a formal investigation to assess (BRIDO)         N           5         STUDY         study_status         Abribute         CNEW         Protocol Version         A plan at a particular point in time for a formal investigation to assess prime product, commerc, care plan, or subject characteristic. (BRIDO)           6         STUDY_status         Abribute         CS1409         Study Type         Study Type; Study Type         A plan at a particular point in time for a formal investigation to assess prime product, commerc, care plan, or subject characteristic. (BRIDO)           7         STUDY_TYPE         Study Type         Study Type; Study Typ			STUDY	STUDY	Entity	C15206	Clinical Study			N
2         Interventional studies) and observational studies. HIMD/Clinical Tables, Official Study         Interventional studies) and observational studies. HIMD/Clinical Tables, Official Study         N           2         STUDY         study_life         Abribule         C49802         Study Tile         Trial Tile; Official Study         N           3         STUDY         study_version         Abribule         C93490         Study Protocol Version         A plan at a particular point infine for a formal investigation to assess the utility, inpact, pharmacological, physicological, and/or psychological effects of a particular treatment, procedue, drug, device, biologic, body rodu, cosmelc, care plan or subjet characteristic (BRDO)         N           4         4         STUDY         study_status         Abribule         CNEW         Protocol Version         A condition of the protocol at a point in time with respect to its state of readiness for inglementation. (BRDO)         N         Aplan at a particular point in time for a formal investigation to assess N         N           6         STUDY         study_protocol_version         Abribule         C142175         Study Type         Study Type: Study Type         Response-define material treatment, procedue, drug, device, psychological effects of a paint or a study information is being To allow and provide cosmet, care plan or subjet characteristic.         N           7         STUDY_TYPE         Study_type_desc         Abribule         C142175										
2         study_status         Attribute         C49602         Study Trite         Trial Trite; Official Study Trite; Study Trite         studes_Inite_/ClinicalTrites.com/(ICDEC.Glossary)         N           4         3         STUDY         study_version         Attribute         C94902         Study Trite         Trial Trite; Official Study Trite; Study Trite         The sponsor-defined name of the clinical study.         N           4         4         STUDY         study_version         Attribute         C93490         Study Protocol Version         A plan at a particular statement, procedure, drug, device, biologic, food product, carenela, or subject characteristic. (BRIDG)         Y (CNE           5         STUDY         study_status         Attribute         C93490         Study Protocol Version         A condition of the protocol at a point in time with respect to its state of regeneration.         Responsor-defined name of the clinical study.         N           6         STUDY         study_protocol_version         Attribute         C9490         Study Type         Study Type: Study Type         A plan at a particular statement, procedure, drug, device, biologic, food product, carenela, or subject characteristic.         N           7         STUDY_TYPE         Study_protocol_version         Attribute         C142175         Study Type: Study Type         Classification         Callestints to point in tine with reset to incorestrastin										
3         2         STUDY         study_Bie         Attribute         C48802         Study Title         Thile: Official Study Title: Study Title         The sponsor defined name of the clinical study.         N           3         3         STUDY         study_version         Attribute         C3490         Study Protocol Version         A plan at a particular point in the for a formal investigation to assess he utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG)         N           4         4         STUDY         study_status         Attribute         CNEW         Protocol Status         Accordition of the protocol at a point in the with respect to its state of readiness for implementation.         Respon psychological effects of a particular treatment, procedure, drug, device, polychological effects of a particular treatment, proceditar treatment, procedure atthe study_Type; Study Type; Study Ty	2									
3         STUDY         study_version         Attribute         C93490         Study Protocol Version         A plan at a particular point in time for a formal investigation to assess in psychological effects of a particular point in time for a formal investigation to assess in psychological cosmetic, care plan, or subject characteristic.           4         5         STUDY         study_protocol_version         Attribute         CNEW         Protocol Status         A condition of the protocol at point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation in asses in psychological affects of a particular point in time for a formal investigation in assess in psychological affects of a particular point in time for a formal investigation to assess in psychological affects of a particular point in time for a formal investigation in assess in psychological affects of a particular point in time for a formal investigation in table in the investigation for which study information is being in psychological affects of a particular point information is being in the nature of the investigation for which study information is being in the nature of the invest	2	2	STUDY	study_title	Attribute	C49802	Study Title	Trial Title; Official Study		N
Image: Construct of the investigation of the produced stars of the investigation of the investigatin of the investigation of the investigation of the inve	3							Title; Study Title		
4         5         5         STUDY         study_status         Attribute         CNEW         Protocol Status         A condition of the protocol at a point in time with respect to its state of (BRIDO)         Y (CNE retainless for implementation.           6         4         STUDY         study_status         Attribute         CNEW         Protocol Status         A condition of the protocol at a point in time with respect to its state of treadness for implementation.         N           6         5         STUDY         study_protocol_version         Attribute         C93490         Study Protocol Version         A plan at a particular point in time for a formal investigation to assess the utility, impact, harmacologi, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, cometic, care plan, or stubjet characteristic. (BRIDO)           6         5         STUDY_TYPE         Entity         C142175         Study Type:         Study Type: Study Type         The nature of the investigation for which study information is being collected. (After clinical trista so collected. (After clinical trista so collinical trista so collected. (After clinical trista	3		STUDY	study_version	Attribute	C93490	Study Protocol Version			N
4         Image: Study_status         Attribute         CNEW         Protocol Status         Accondition of the protocol at a point in time with respect to its state of readiness for implementation.         CNEW           5         STUDY         study_protocol_version         Attribute         CNEW         Protocol Status         Acondition of the protocol at a point in time with respect to its state of readiness for implementation.         Response to the utility, impact, pharmacological, physiological, and/or psychological effects of a particular resultment. Procedure, drug, device, biologic, leod product, cosmetic, care plan, or subject characteristic.         N           6         6         STUDY_TYPE         STUDY_TYPE         Study Type; Study Type; Study Type; Classification         The nature of the investigation for which study information is being collected. (Adver clinicatitinas gov)         N           7         STUDY_TYPE         study_type_desc         Attribute         C142175         Study Type; Study Type; Classification         The nature of the investigation for which study information is being collected. (Adver clinicatitinas gov)         N           7         STUDY_PHASE         STUDY_PHASE         Study Type; Classification         Study Type; Study Type; Classification         Classification         Calssification         Collected. (Adver clinicatitinas gov)         N           9         STUDY_PHASE         STUDY_PHASE         STUDY_PHASE         STUDY_PHASE         Study Iphase_Class										
4       Image: Study_status       Attribute       CNEW       Protocol Status       A condition of the protocol at a point in time with respect to its state of readiness for implementation.       Response in the status of readiness for implementation.       N         5       STUDY       study_protocol_version       Attribute       C93490       Study Protocol Version       A plan at a particular point in time with respect to its state of psychological and/or psyc										
4         STUDY         study_status         Attribute         CNEW         Protocol Status         A condition of the protocol at a point in time with respect to its state of readiness for implementation.         Y (CNE Response)           5         STUDY         study_protocol_version         Attribute         C93490         Study Protocol Version         A plan at a particular resement, procedure, drug, device, device, de										
5         Image: Construction of the construction of t	-+		STUDY	study status	Attribute	CNEW	Protocol Status			Y (CNEW Protocol Stat
Image: Construct of the investigation for which study information is being psychological, or which study information is being collected. (After clinical traits are plan, or subject characteristic. (RRIDG)         N           7         STUDY_TYPE         STUDY_TYPE         STUDY_Lype_desc         Attribute         C142175         Study Type         Study Type: Study Type         The nature of the investigation for which study information is being collected. (After clinical traits gov)         N           7         STUDY_TYPE         study_type_desc         Attribute         C142175         Study Type: Study Type: Collected. (After clinical traits gov)         Y         C2980           8         STUDY_PHASE         STUDY_PHASE         STUDY_PHASE         Entity         C48281         Trial Phase; Trial Phase         Classification         Classification collected. (After clinical traits gov)         Y         C2980           9         STUDY_PHASE         STUDY_PHASE         Entity         C48281         Trial Phase         Trial Phase; Trial Phase         Classification         A step in the clinical research and development of a therapy from initial N clinical traits are generally categorized info four (sometimes five phases.) Attribute         CG882           9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase; Trial Phase; Trial Phase; Trial Phase; Clinical trials are generally categorized in four (sometimes five phases.) Attribute         CG	5	.								Response)
6         Image: Study_TYPE         Study_TYP	5	;	STUDY	study_protocol_version	Attribute	C93490	Study Protocol Version		A plan at a particular point in time for a formal investigation to assess	N
6       iologic, food product, cosmetic, care plan, or subject characteristic. (BRDG)       iologic, food product, cosmetic, care plan, or subject characteristic. (BRDG)         7									the utility, impact, pharmacological, physiological, and/or	
6       Image: Construction of the investigation of the investing and prestal investice inthe investigation of the i										
6         STUDY_TYPE         STUDY_TYPE         Study Type         Study Type         Study Type         The nature of the investigation for which study information is being collected. (After clinicaltrials.gov)         N           7         STUDY_TYPE         study_type_desc         Attribute         C142175         Study Type         Study Type         The nature of the investigation for which study information is being collected. (After clinicaltrials.gov)         Y (C390 collected. (After clinicaltrials.gov)           8         STUDY_PHASE         STUDY_PHASE         STUDY_PHASE         Entity         C48281         Trial Phase; Trial Phase; Trial Phase; Trial Phase         A step in the clinical trias to post-approval studies. VOTE: Clinical triatis are generally categorized into four (sometimes five) phases. A therapoulic intervention may be evaluated in two or more phases simultaneously intervention may be evaluated in two or more phases. Simultaneously intervention may be evaluated in the or more phases. (LNICAL TRIALS, CPMP/ICH/291/95 March 1998)           9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase Classification         Trial Phase; Trial Phase (Classification         A step in the clinical trias to wor trias generally categorized into four (sometimes five) phases. A therapoulic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. Simulaneousty GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/										
7       STUDY_TYPE       study_type_desc       Attribute       C1assification       collected. (After clinicaltrials.gov)         8       STUDY_TYPE       study_type_desc       Attribute       C142175       Study Type Classification       Classification       Collected. (After clinicaltrials.gov)       Y (C398)         8       STUDY_PHASE       STUDY_PHASE       STUDY_PHASE       Entity       C48281       Trial Phase       Trial Phase; Trial Phase; Trial Phase       A step in the clinical research and development of a therapy from initial or or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. Study CPM PiCH/291/95 March 1998]       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase; Trial Phase; Trial Phase; Trial Phase; CMSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase; Trial					Entity	0140175	Chudu Tumo	Study Type: Study Type	· · · · · ·	N
7       STUDY_TYPE       study_type_desc       Attribute       C142175       Study Type Classification       Study Type Classification       The nature of the investigation for which study information is being collected. (After clinical trials gov)       Y (C980)         8       STUDY_PHASE       STUDY_PHASE       STUDY_PHASE       Entity       C48281       Trial Phase       Trial Phase: Trial Phase       A step in the clinical research and development of a therapy from initial or clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. At herapeutic clinical trials and some trials may overlap two different phases. [21]         9       9       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase; Constitutions Fort CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]       A step in the clinical traits and development of a therapy from initial Y (C667); CPMP/ICH/291/95 March 1998]         9       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase; Classification       A step in the clinical traits and therapy from initial Y (C667); CPMP/ICH/291/95 March 1998]       A step in the clinical traits are generally categorized into four (sometimes five) phases.] (21)       CFR section 312	7 0	· ·	SIUDI_ITPE	STUDT_TTPE	Enuty	0142175	Study Type			IN .
8         10         10         Classification         collected. (After clinical trials.gov)           8         STUDY_PHASE         Study_phase_desc         Attribute         C48281         Trial Phase         Classification         C	7	,	STUDY TYPE	study type desc	Attribute	C142175	Study Type Classification			Y (C99077 STYPE)
9       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase Classification       Classification       clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312 21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]         9       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase Classification       Trial Phase; Trial Phase       A step in the clinical trass to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases. Simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312 21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL. CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]         10       STUDY_IDENTIFI STUDY_DENTIFIER       Entity       C83082       Study Identifier       A sequence of characters used to identify, name, or characterize the study.         11       STUDY_IDENTIFI org_code       Attribute       CNEW       Study Identifier Organization       A coded value specifying the organization that creates and/or assigns       N	8						, .,,			. (,
9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase Classification         Trial Phase; Trial Phase; Trial Phase         A step in the clinical research and development of a therapy from initial are generally categorized into or more phases. At therapeutic intervention may be evaluated in two or more phases. Trial Phases; 121           9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase; Trial Phase; Trial Phase; Trial Phase         A step in the clinical research and development of a therapy from initial are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases. At therapeutic clinical triats to post-approval studies. NOTE: Clinical triats to post-approval studies. NOTE: Clinical triats to post-approval studies. NOTE: FOR GUIDANCE ON GENERAL: CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]           10         STUDY_DENTIFI         STUDY_LDENTIFI         Entity         C683082         Study Identifier         A sequence of characters used to identify, name, or characterize the study.         N           11         STUDY_DENTIFI         STUDY_DENTIFI         CNEW         Study Identifier Organization         A coded value specifying the organization that creates and/or assigns         N	8	3	STUDY_PHASE	STUDY_PHASE	Entity	C48281	Trial Phase	Trial Phase; Trial Phase	A step in the clinical research and development of a therapy from initial	N
9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase Classification         Trial Phase; Trial Phase; Trial Phase; Trial Phase         Attribute         C48281         Trial Phase; Classification         Classification         Attribute         Attribute         C48281         Trial Phase; Trial Phase; Trial Phase; Trial Phase; Trial Phase; Classification         Trial Phase; Trial Phase; Trial Phase; Classification         Classification         Attribute         Attribute         C48281         Trial Phase; Classification         Classification         Attribute         Attribute         C48281         Trial Phase; Classification         Trial Phase; Trial Phase; Trial Phase; Classification         Classification         Attribute         Attribute         C48281         Trial Phase; Classification         Classification         Attribute         Attribute         C48281         Trial Phase; Classification         Classification         Attribute         Attribute         C48281         Trial Phase; Classification         Classification         Attribute; Classification         Classification         Attribute; Classification         Classification         Attribute; Classification         Classification         Classification         Classification         Classification         Classification         Classification         Classification         Classification         Classificaticlasis and some trials and some trials may overlap two different								Classification		
9         In different trials, and some trials may overlap; two different phases, [21] CFR section 312.21; After ICH Topic E8 NOTE FOR QUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/29195 March 1998]           9         STUDY_PHASE         study_phase_desc         Attribute         C48281         Trial Phase Classification         Trial Phase; Trial Phase Classification         A step in the clinical research and development of a therapy from initial generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in two or more phases. A therapeutic intervention may be evaluated in the organization that creates and/or assigns. A CPMP/ICH/291/95 March 1998]           10         STUDY_DENTIFI         STUDY_IDENTIFIER         Entity         C83082         Study Identifier         A coded value specifying the organization that creates and/or assigns. N										
9       Image: Study_PHASE       study_phase_desc       Attribute       C48281       Trial Phase Classification       Trial Phase; Trial Phase; Clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. Attribute       C48281       Trial Phase; Classification       A step in the clinical research and development of a therapy from initial Y (C667) clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. Attribute       C48281       Trial Phase; Classification       A step in the clinical research and development of a therapy from initial Y (C667) clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. Attribute       C (Cassification and trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. Attribute         10       Image: Study_IDENTIFI       STUDY_IDENTIFI       Entity       C83082       Study Identifier       A sequence of characters used to identify, name, or characterize the study.       N         11       STUDY_IDENTIFI       Org.       Attribute       CNEW       Study Identifier Organization       A coded value specifying the organization that creates and/or assigns       N										
9       Image: Study_PHASE       study_phase_desc       Attribute       C48281       Trial Phase Classification       Trial Phase; Trial Phase; Trial Phase; Trial Phase       A step in the clinical raise and development of a therapy from initial of post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. Atterapeutor in the clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. Atterapeutor in there intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; Atter ICH Topic EB NOTE FOR GUIDANCE ON GENERAL. CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]       N         10       STUDY_IDENTIFI STUDY_IDENTIFIER       Entity       C83082       Study Identifier       A sequence of characters used to identify, name, or characterize the study.       N         11       STUDY_IDENTIFI org_code       Attribute       CNEW       Study Identifier Organization       A coded value specifying the organization that creates and/or assigns       N										
9       STUDY_PHASE       study_phase_desc       Attribute       C48281       Trial Phase Classification       Trial Phase; Trial Phase       A step in the clinical research and development of a therapy from initial Y (C66)         10       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       org_code       Attribute       C48281       Trial Phase Classification       Trial Phase; Trial Phase       A step in the clinical research and development of a therapy from initial Y (C66)         10       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       C83082       Study Identifier       A step in the clinical research and development of a therapy from initial Y (C66)         11       STUDY_IDENTIFI       STUDY_IDENTIFI       C83082       Study Identifier       A step in the clinical research and development of a therapy from initial Y (C66)         11       STUDY_IDENTIFI       STUDY_IDENTIFI       C63082       Study Identifier       A sequence of characters used to identify, name, or characterize the study.       N										
10       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       STUDY_IDENTIFI       Cassification       Classification       clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic in theremosin may be evaluated in two or more phases similaneously in different trials, and some trials may overlap two different phases. If CFR section 312.21; After ICH Topic BN OTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]         10       STUDY_IDENTIFI       STUDY_IDENTIFI       CR3082       Study Identifier       A sequence of characters used to identify, name, or characterize the study.       N         11       STUDY_IDENTIFI org_code       A ttribute       CNEW       Study Identifier Organization       A coded value specifying the organization that creates and/or assigns       N	9								CPMP/ICH/291/95 March 1998]	
Image: second	9	)	STUDY_PHASE	study_phase_desc	Attribute	C48281	Trial Phase Classification	Trial Phase; Trial Phase	A step in the clinical research and development of a therapy from initial	Y (C66737 TPHASE)
10     10     STUDY_IDENTIFI STUDY_IDENTIFIER     Entity     C83082     Study Identifier     A sequence of characters used to identify, name, or characterize the study.       11     STUDY_IDENTIFI org_code     A ttribute     CNEW     Study Identifier Organization     A coded value specifying the organization that creates and/or assigns     N								Classification		
Image: second										
Image: study in the s										
Image: study in the s										
International Control of Control										
10         STUDY_IDENTIFI         STUDY_IDENTIFIER         Entity         C83082         Study Identifier         A sequence of characters used to identify, name, or characterize the study.         N           11         STUDY_IDENTIFI         org_code         Attribute         CNEW         Study Identifier Organization         A coded value specifying the organization that creates and/or assigns         N	10								CPMP/ICH/291/95 March 1998]	
ER         ER         study.           11         STUDY_IDENTIFI         org_code         Attribute         CNEW         Study identifier Organization         A coded value specifying the organization that creates and/or assigns         N		0	STUDY_IDENTIFI	STUDY_IDENTIFIER	Entity	C83082	Study Identifier		A sequence of characters used to identify, name, or characterize the	N
	11									
				org_code	Attribute	CNEW			, , , , , , , , , , , , , , , , , , , ,	N
	12		ER			ONEW	Code		the study identifier.	
12 The literal identifier (i.e., distinctive designation) of the sequence	1	2	-			NEW	Study identifier Name			EXCE



### PDF

### **User Stories**

Dave Iberson-Hurst, 21st March 2022

#### Changes

- 25<sup>th</sup> January 2022 Initial draft
- 31<sup>st</sup> January 2022 Updates after informal review
- 14<sup>th</sup> Febraury 2022 Updates after initial Transcelerate (TCB) review. Includes better alignment with TCB terminology. Also the Essential User Stories and those raised as JIRA tickets have been incorporated such they can viewed in context.
- 21<sup>st</sup> March 2022 Updates after further review.

#### Purpose

This note presents a set of user stories for the Digital Data Flow Project based on the essential user stories produced by the project to date. The presented user stories try and respond to comments raised on the essential user stories such as the following JIRA ticket.

However the users of the USDM are the upstream and downstream systems and not directly the users of those systems. So search and add/remove functions like described in user story L1 to L5 are not directly applicable to the USDM and RA. However, the data structure must make it possible for the upstream system to provide this functionality. So a logical data structure and API requests are in scope. Can the user stories be adjusted to reflect this?





### PDF

### **Architecture Principles**

Description of the Deliverable for the Development Phase

The architecture principles aim to help implementers understand how to create conformant solution architectures through the implementation of the DDF Study Definition Reference Architecture (RA). They inform solution architects of the approach expected by the RA stakeholders to ensure consistency across Study Definition implementations and to ensure alignment with the business and technology objectives. Architecture principles define the fundamental assumptions regarding the RA and aid in developing a framework for decision making by solution architects implementing the RA.

Summary of work to be performed during scoping

A framework for the architecture principles was developed during the scoping period.





#### **Supporting Materials**

A set of informational materials in PDF format to help understand the deliverables being reviewed. PDF documents or references.

- Issues and Questions: Based on the remaining JIRA • tickets a series of issues and question to be addressed during the review.
- Technical Notes: Technical notes on Schedule of • Activities and ODM/CRF creation
- High-Level Model Overview: Aid to reviewing the • model
- •


#### **CRF Specification for DDR**

DDR-Umbrella Study of DNA-Damage Response Targeting Agents in Advanced Biliary Tract Cancer

#### Protocol Name: Targeting Agents in ABTC

CRF Creation date: 2022-03-15T15:46:39

#### **Table of Contents**





ARTHOAT 1 1

AGE 1.2

AGEU 1.3

SEX

RACE 1.6

BACEOTH 1 7

.......

....

ETHNC 1.5

CRF Stylesheet courtesy of: Jørgen Mangor Iversen, Leo Pharma A/S

# **CDISC Study Definition Repository RA Deliverables**



#### Unified Study Definitions Model (USDM) Class Diagram

The UML class diagram (normative) as well as SQL Data Dictionary, Entity Relationship Diagram and example JSON output (informative)



#### Application Programming Interface (API) Specification The API definition (normative) in JSON and HTML forms



#### **CDISC Controlled Terminology**

The controlled terminology (normative) developed for the project. Provided in an Excel format so as to be easily searched and filtered.



#### **Reference Architecture Conformance Tests**

Provided by the functionality provided by tools such as SwaggerHub and Postman



#### **Essential Users Stories** The User Stories. PDF document



\$ \$ \$

#### Architecture Principles

The architectural principles developed by the project. PDF Document



A set of informational materials in PDF format to help understand the deliverables being reviewed. PDF documents or references.






- 2. TransCelerate and DDF
- 3. CDISC DDF standards for public review
- 4. Public Review Process
- 5. Q&A

#### \*Minimal Viable Product

### **The Process for MVP**





#### \*Minimal Viable Product

### **Timelines for the MVP\***

2021	Jan	Feb	Mar	Apr	Мау	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Stage 0	Scoping and Planning Identification/Modeling c
DDF								Stage 0		w1 Sta	ge 1/2		Stage 1/2 Stage 3a	Standards Development Internal Review
										3a	<u>3a</u>		Stage 3b Stage 3c	Public Review Publication
2022	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	<b>w</b>	Public Webinars 1 - Scoping Results 2 - Public Review
DDF		Stage 1/2		Stage 3b	3C	W3								3 - Publication
	3a	3a												
			/											



of Concepts



### **Public Review Timetable**

- Tuesday 22<sup>nd</sup> March 2022 DDF Public Review Webinar
- Tuesday 29<sup>th</sup> March 2022 DDF Materials sent out for review Start of 30day public review
- Monday 4<sup>th</sup> April 2022 10:00-11:00 US Eastern Time DDF Public Review Workshop – open invite (details on the DDF Public Review Webinar Page)
- Friday 29th April 2022 DDF Public Review Commenting Period ends





#### **Public Review Materials**

- Email will be sent from CDISC Communications
- Public Review information will also be available from the Public Review section of the CDISC website
  - <u>https://www.cdisc.org/public-reviews</u>
  - <u>https://www.cdisc.org/ddf</u>

					Log out My Account
cdisc		New to CDISC St	andards Education	Resources Events	Membership Members Only
Home / Public Reviews	Foundational	Data Exchange	Therapeutic Areas	Standards	CDISC Library
	BRIDG	CTR-XML	Alphabetical	Publications	CDISC Library Archives
Public Reviews	PRM	Dataset-XML	By Disease Area	In Development	Real World Data
	SEND	Define-XML	Published User Guides	Public Reviews	FHIR-CDISC
Standard/Therapeutic Area	CDASH	LAB		Standards in Development	Vaccine Administration
Controlled Terminology Paci	SDTM	ODM-XML		CDISC 360	
Controlled Terminology Paci	SDTMIG	RDF		CORF	
	ADaM	SDM-XML		Digital Data Flow	
	QRS	Terminology		Logran Data ( 104	
	Medical Devices	Glossary			
	PGx	Controlled Terminology			

• Links will direct reviewers to the DDF Public Review Dashboard




#### **DDF Public Review Dashboard**

conse stan	ndards Deve	elopment Process				
		The DDF Standards are now entering the public review commenting				
		The purpose of the Abilit Review is to develop widespeed content     Additional information on the overall aims of the 200 <sup>2</sup> project     Additional information is wailable in the TransCeletate press	ct can be found on the TransCelerate DDF	for broad comment by the general public. Anyone interested may review and submit of Website	mments which must be reviewed and addressed by teams before proceeding	
Public Review T	Timelines	0				
		od will be open for 30-days.				Timelines
Public Review Commenting Start Date - 10 28 Mar 2022 Public Review Commenting Start Date - 10 28 Apr 2022					Timetimes	
Public Kerlew Comm	enong end bate	· E za vbi zocz				
Public Review V						
A recording of the Pu Webinar Summary	Jblic Review We	binar from 22nd March 2022 can be found here < <insert link="">&gt;. It is recommended that you watch this recording to gain a deeper understanding o</insert>	of the materials that are being sent for Pul	lic Review. The slide deck < <insert link="">&gt; used in the webinar is also available.</insert>		
Торіс		Presenter Timing				
Webinar Introductio	on	Dave Evans				Webinar
TransCelerate and D	DDF	Alison Luciman				VEDITAL
CDISC DDF standar	ds for public rev	vlew Dave Iberson-Hurst				
Public Review Proce	855	John Owen				
Q&A		All				
<ul> <li>The DDF</li> </ul>	e aware that sor review team is	me of the deliverables that are being developed may be out of your still set. made up of experts in all the areas that the deliverables cover. ments that you can provide that you can provide input on.				
<ul> <li>Please be</li> <li>The DDF</li> </ul>	e aware that sor review team is	made up of experts in all the areas that the deliverables cover.	Files Available for Fublic Review	Files		
Please bi     The DDF     We apprend  Deliverable Unified Study	e aware that sor review team is eclate any comm	made up of experts in all the areas that the deliverables cover. ments that you can provide that you feel you can provide input on.	Public Review PDF export from	Files		
Please bi     The DDF     We appro  Deliverable	e aware that sor review team is eclate any comr CDISC Standard	made up of experts in all the aneat that the deliverables cover. ments that you can provide that you feel you can provide input on.	Public Review	Files		Materials
Please bi     The DDF     We apprend  Deliverable Unified Study Definitions Model (USDM) Class	e aware that sor review team is eclate any comr CDISC Standard	made up of experts in all the areas that the defineables cover.  Interst that you can provide that you van provide input on.  What would people Review  The UVL class dagram (normative) as well as SQL Data Dictionary. Entry Relationship Diagram and example JSON output (informative)  O Need some info os UMM2	Public Review PDF export from	Files		Materials
Please by The DDF We appn  Deliverable  Unified Study Definitions Model (USDM) Class Diagram	e aware that sor i review team is : eclate any comm CDISC Standard Yes	made up of experts in all the areas that the defineables cover.  Rest that you can provide that you van provide input on.  What would people Review  The UVL, class diagram (normative) as well as SQL Data Dictionary, Entity Relationship Diagram and example (SON output (informative)  O Need some info on UNI2  If you are unfamiliar with UML Section 5.6 of the BROG Uses Guide might be used as a model for a "Balcs of UML" guide for DDF	Public Review PDF export from Enterprise Architect JSON and HTML	Files  Files  DDF Controlled Terminology, Skills Review, FilvAL.lss		Materials
Please by The DDF We approve Unified Study Definitions Model (USDM) Class Diagram API Specification Controlled	e aware that sorr review team is reclate any comm CDISC Standard Yes Yes	made up of experts in all the areas that the deliverables cover.	Public Review PDF support from Enterprise Architect //SON and HTML formats Excel format (for exce of searching			Materials
Please by The DDF We appn      Deliverable  Unified Study Definitions Model (USDM) Class Diagram      API Specification      Controlled Terminology Essential User	e aware that tors review team is sclate any comm CDISC Standard Yes Yes Yes Yes	made up of experts in all the area that the deliverables cover.  Interst that you can provide that you feel you can provide input on.  What would people Review  The UML class dagram (normative) as well as SQL Data Dictionary, Ently Relationship Diagram and example JSON output (informative)  Need some infor on UMI2  () Need some infor on UMI2  () The API definition.  The controlled terminology (normative) developed for the project.	Public Review DD # upon from Entraprise Architect //SON and HTML formats Excel format for each of sarching and filtering).			Materials
Prese to the 200     The 200     We appreciate the 200     We appreciate the 200     Work appreciate the 200	e evare that ion review team is in eclate any comm CDISC Standard Yes Yes Yes Yes No	made up of experts in all the area that the deliverables cover.	Public Review PDF sport from DF sport from Strarprise Architect ISON and HTML Commas Local Format for used of searching and filtering) FDD Decument	DDF Controlled Terminology, Sublic Review, ETNAL.tex		Materials
Place be The DDP     Velepin	e aware that portunities that portunitie	make up of experts in all the area that the deliverables cover.     meets that you can provide they you can provide input on.	Public Review 2019 aport from Compared Automate 2019 aport from Compared Automate 2010 and HTML Itomate 2010 Consumert 2010 Document 2010 Docu	DDF Controlled Terminology, Sublic Review, ETNAL.tex		Materials
Place be The DDP     Velepin	e aware that portunities that portunitie	make up of people share are that the defineables cover.     meets that you can provide that you real provide input on.      What would people Review      The UVL clust diagram (normative) as well as SQL Data Dictionary. Entity Relationship Diagram and example JSON output (Informative)      The UVL clust diagram (normative) as well as SQL Data Dictionary. Entity Relationship Diagram and example JSON output (Informative)      The UVL clust diagram (normative). Sector 5.6 of the BROB Users Guide might be used as a model for a "Tasics of UVL" guide for DDF      The API definition.      The controlled terminology (normative) developed for the project.      The Uter Sonies.      The architectural principles developed by the project.      A set of informational materials in PDF format to help understand the deliverables being reviewed.	Public Review 2019 aport from Compared Automate 2019 aport from Compared Automate 2010 and HTML Itomate 2010 Consumert 2010 Document 2010 Docu	DDF Controlled Terminology, Sublic Review, ETNAL.tex		Materials

Register for the write in you aready have an account on write or

### **Questions & Answers**





#### Do I need to become a CDISC volunteer to take part in the public review?




40



Will you send out a list of resolutions to public review comments?








## What study types will you cover in the DDF initiative?



42



Will the DDF model also enable automation of disclosure of study protocols/results to CT.gov, EU CTR CTIS portal, etc?









Is there a concern that any technology recommendation will show a bias towards a particular implementation and ultimately hurt the ability to innovate?






Is there a standard computable study protocol schema for study builder, study repository and downstream application RWD use?










Is the open source license planned to be permissive or copy left?





## Can you elaborate on the public connectathon?







One of the slides mentioned Biomedical Concepts as a CDISC standard. Is that currently an approved standard and how does it integrate with USDM?



#### **Upcoming Learning Opportunities**





- Information available at: www.cdisc.org
- Register at: <u>https://learnstore.cdisc.org/</u>
- Contact us at: <u>training@cdisc.org</u>









TRAINING





#### **Free CDISC Courses**

C	disc				电 Log In 🎽
kome	Upcoming Trainings All Courses	Calendar Help	CDISC Learning System Q		
All	Courses				
Filter	by Tags			Courses p	per page: 10 💙
	CDASH	cdi			\$0.00 Quantity
	Controlled Terminology ODM Define XML SEND		Course DescriptionThis training implement + Learn More	g outlines how academic and research organizz	titions can
		cdi	CDISC for Standards P On Demand	ublic Reviewers	\$0.00 Quantity
			The CDISC for Standards Publi (TA) + Learn More	ic Reviewers training provides a history of the 1	Therapeutic Area
0	Course Type			~	dd to Cart
0	Virtual Events				
0	Time Zone	cdi	CDISC Newcomers We	binar	\$0.00 Quantity
o	Course Level		+ Learn More		
0 0	Course Region Certification			~	dd to Cart

cdisc

#### Http://learnstore.cdisc.org

51

#### 2022 EUROPE INTERCHANGE cdisc virtual conference

27-28 APRIL

#### 2022 JAPAN INTERCHANGE CDISC VIRTUAL CONFERENCE 13-14 JUNE

........

## COSA OpenStudyBuilder Workshop Friday, April 29th Register for FREE!

Register on the Europe Interchange registration page – no requirement to register for the main conference.

The OpenStudyBuilder is an open-source project for clinical study specification. This tool is a new approach for working with studies that once fully implemented will drive end-to-end consistency and more efficient processes - all the way from protocol development and CRF design - to creation of datasets, analysis, reporting, submission to health authorities and public disclosure of study information.





#### 2022 CHINA INTERCHANGE 29 - 30 JULY | BEIJING



# 26-27 OCTOBER | AUSTIN, TX





#### **Upcoming Webinars**

Date	Webinars
24 March	Introduction to the SDTM Genomics Finding (GF) Domain
29 March	SDTM Office Hours
31 March	CDISC Open Source Alliance (COSA) Spotlight
5 April	Controlled Terminology Updates for Q1 – P49 Publication / P50 Public Review
19 April	QRS Office Hours
28 June	Controlled Terminology Updates for Q2 – P50 Publication / P51 Public Review
	Ideas or suggestions for webinar topics? Any topics you would love to see us cover?
	Let us know via our topic suggestion form:




.........

#### Why Become a Member?

- To ensure the CDISC standards remain open and free
- To support CDISC in the development and maintenance of global standards
- To work with the CDISC community and be a voice in the development of clinical research standards
- To impact the development of regulatory requirements for submissions
- To access members only resources and benefits

cdisc

• To gain visibility in the marketplace



#### **CDISC MEMBERSHIP**

#### **Become a Member!**

Join nearly 500 member organizations that contribute to bringing clarity to data.

#### Already a Member?

Thank you! It is our members' support which enables us to develop standards, keeping it free and accessible to all.





## Thank you!



Contact the Events inbox: <a href="mailto:events@cdisc.org">events@cdisc.org</a>



Contact Education inbox: training@cdisc.org



Contact Bernard directly: bklinke@cdisc.org

